Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crimson 1: MarzAA in Hemophilia A or B with Inhibitors
NCT04489537Phase 3Terminated
- Sponsor
- Gyre Therapeutics, Inc.
- Start
- May 2021
- Primary completion
- Nov 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 16
01
Overview
A Phase 3 trial of marzeptacog alfa (activated) in hemophilia A, hemophilia B (HB), sponsored by Gyre Therapeutics, Inc.. Started May 2021; status: terminated.
02
Drugs
marzeptacog alfa (activated)
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT04489537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04489537.